Back to today’s briefing

Story perspectives

Insmed Stock Soars 28.7% on Drug Success

6/11/2025

46 9

Summary

Story summary

Insmed's stock skyrocketed by 28.7% following promising results for its inhaled drug, treprostinil palmitil, targeting pulmonary arterial hypertension (PAH). The treatment demonstrated a remarkable 35% reduction in pulmonary vascular resistance and boosted patients' six-minute walk distance. Analysts foresee a potential 15-25% increase in stock value, while rivals United Therapeutics and Liquidia faced declines.

1 of 1

Story summary

Insmed's stock skyrocketed by 28.7% following promising results for its inhaled drug, treprostinil palmitil, targeting pulmonary arterial hypertension (PAH). The treatment demonstrated a remarkable 35% reduction in pulmonary vascular resistance and boosted patients' six-minute walk distance. Analysts foresee a potential 15-25% increase in stock value, while rivals United Therapeutics and Liquidia faced declines.